DE602006021408D1 - Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien - Google Patents

Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien

Info

Publication number
DE602006021408D1
DE602006021408D1 DE602006021408T DE602006021408T DE602006021408D1 DE 602006021408 D1 DE602006021408 D1 DE 602006021408D1 DE 602006021408 T DE602006021408 T DE 602006021408T DE 602006021408 T DE602006021408 T DE 602006021408T DE 602006021408 D1 DE602006021408 D1 DE 602006021408D1
Authority
DE
Germany
Prior art keywords
treatment
hpv
antigens
induced
neoplasia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602006021408T
Other languages
German (de)
English (en)
Inventor
Der Burg Sjoerd Hendricus Van
Rienk Offringa
Cornelis Johannes Melief
Theodorus Jozef Helmerhorst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leids Universitair Medisch Centrum LUMC
Original Assignee
Leids Universitair Medisch Centrum LUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leids Universitair Medisch Centrum LUMC filed Critical Leids Universitair Medisch Centrum LUMC
Publication of DE602006021408D1 publication Critical patent/DE602006021408D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602006021408T 2005-04-27 2006-04-25 Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien Expired - Lifetime DE602006021408D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05103447 2005-04-27
PCT/NL2006/050099 WO2006115413A2 (en) 2005-04-27 2006-04-25 Methods and means for the treatment of hpv induced intraepithelial neoplasias

Publications (1)

Publication Number Publication Date
DE602006021408D1 true DE602006021408D1 (de) 2011-06-01

Family

ID=35583560

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006021408T Expired - Lifetime DE602006021408D1 (de) 2005-04-27 2006-04-25 Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien

Country Status (10)

Country Link
US (2) US7807369B2 (https=)
EP (2) EP1874312B1 (https=)
JP (1) JP5106384B2 (https=)
CN (1) CN101189014A (https=)
AT (1) ATE506063T1 (https=)
AU (1) AU2006240561B2 (https=)
CA (1) CA2609927A1 (https=)
DE (1) DE602006021408D1 (https=)
ES (1) ES2363247T3 (https=)
WO (1) WO2006115413A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009012922A (es) * 2007-05-31 2010-07-05 Academisch Ziekenhuis Leiden H Vacunacion intradermica de un peptido del virus del papiloma humano.
CN102686720B (zh) * 2009-11-17 2013-12-04 国立大学法人冈山大学 由牙髓细胞向成牙本质细胞的分化诱导方法
EP2508190B1 (en) * 2009-12-03 2021-06-02 Aureo Co., Ltd. Macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages
US20150310003A1 (en) * 2014-04-28 2015-10-29 Elwha Llc Methods, systems, and devices for machines and machine states that manage relation data for modification of documents based on various corpora and/or modification data
WO2017015504A1 (en) * 2015-07-21 2017-01-26 Scheibel Steven Frederick Treatment and prevention of anal conditions
ES3055492T3 (en) 2015-09-16 2026-02-12 Dfb Soria Llc Delivery of drug nanoparticles and methods of use thereof
WO2017083963A1 (en) 2015-11-18 2017-05-26 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant
CN106632694B (zh) * 2017-01-24 2021-02-12 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
WO2018170196A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
WO2018170210A1 (en) * 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
RU2682783C2 (ru) * 2017-06-14 2019-03-21 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ ОММ" Минздрава России) Способ лечения цервикальных интраэпителиальных неоплазий i степени, ассоциированных с впч высокого онкогенного риска, с использованием кавитированного раствора панавира
EP3765035A4 (en) 2018-03-16 2021-10-27 DFB Soria, LLC TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND COLD CANCER USING TAXANE NANOPARTICLES
CN109614613B (zh) 2018-11-30 2020-07-31 北京市商汤科技开发有限公司 图像的描述语句定位方法及装置、电子设备和存储介质
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CN111905201A (zh) * 2020-08-18 2020-11-10 珠海市索利达医疗器械有限公司 一种生殖道hr-hpv治疗设备
CN114409744B (zh) * 2022-03-29 2022-10-04 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用
CN119529069B (zh) * 2025-01-22 2025-07-01 成都迈科康生物科技有限公司 一种抗hpv16和/或hpv18型e2蛋白的抗体、抗体偶联物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ538399A (en) * 1997-08-05 2007-05-31 Nventa Biopharma Corp Fusion protein comprising an HPV E7 protein and a stress protein wherein the E7 protein is joined directly to the amino terminus of the stress protein
HU229441B1 (en) 1999-01-08 2013-12-30 3M Innovative Properties Co Formulations and methods for treating mucosal associated conditions with an immune response modifier
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
NZ523408A (en) * 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment
AU2002219711B8 (en) 2000-12-08 2006-03-02 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
EP1288292A1 (en) * 2001-08-31 2003-03-05 Leids Universitair Medisch Centrum Long peptides of 22-40 amino acid residues that induce and/or enhance antigen specific immune responses.
GB0105606D0 (en) * 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
CA2467723C (en) * 2001-12-17 2011-09-27 Zymogenetics, Inc. Method for treating cervical cancer
EP1663222A4 (en) * 2003-09-02 2008-05-21 3M Innovative Properties Co METHODS RELATING TO THE TREATMENT OF GIANCES
EP1720567A2 (en) * 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma

Also Published As

Publication number Publication date
US20090060870A1 (en) 2009-03-05
AU2006240561B2 (en) 2011-06-02
WO2006115413A2 (en) 2006-11-02
WO2006115413A3 (en) 2007-04-19
ES2363247T3 (es) 2011-07-28
AU2006240561A1 (en) 2006-11-02
JP2008539228A (ja) 2008-11-13
EP2289516B1 (en) 2014-01-08
US7807369B2 (en) 2010-10-05
EP1874312A2 (en) 2008-01-09
CN101189014A (zh) 2008-05-28
EP1874312B1 (en) 2011-04-20
ATE506063T1 (de) 2011-05-15
CA2609927A1 (en) 2006-11-02
EP2289516A1 (en) 2011-03-02
US20110008287A1 (en) 2011-01-13
JP5106384B2 (ja) 2012-12-26

Similar Documents

Publication Publication Date Title
ATE506063T1 (de) Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
WO2008013454A3 (en) Immunogenic compounds and protein mimics
TW200512457A (en) Method of diagnosing SARS corona virus infection
NZ590890A (en) Neutralizing anti-influenza a virus antibodies and uses thereof
RU2017132160A (ru) Антитела к pd-l1 и их применение для усиления функции t-клеток
IL188460A0 (en) Diagnostic methods and compositions for diagnosing and treating influenza
WO2005089164A3 (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
DE50214416D1 (de) Vermehrung von viren in zellkultur
AR039005A1 (es) Antigenos virales
EP1553975A4 (en) OPTIMIZED FC VARIANTS AND MANUFACTURING METHOD THEREFOR
MY183134A (en) Anti-cemx antibodies capable of binding to human mlge on b lymphocytes
WO2007121894A3 (en) Hpv-18-based papillomavirus vaccine
EP2275816A3 (en) Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
JP2018525453A5 (https=)
NZ611168A (en) Monoclonal antibody recognizing human papilloma virus (hpv) l2 protein and method for measuring hpv-neutralizing antibody titer using the same
MX2009014246A (es) Antigeno de vacuna con la capacidad de inducir anticuerpo de neutralizacion y reaccion cruzada contra virus de papiloma humano del tipo de alto riesgo.
CY1110098T1 (el) Βιομηχανικη μεθοδος για τη παρασκευη της γαμμα-λακτονης του 17-υδροξυ-6-βητα,7-βητα, 15-βητα,16-βητα-δις-μεθυλενο-3-οξο-17-αλφα πρεγκν-4-ενο-21-καρβοξυλικου οξεος και ενδιαμεσα κλειδια για την μεθοδο αυτη
NO20066078L (no) Metode for fremstilling av Entecavir og nye mellomprodukter derav via karbon-silisium oksidasjon
WO2005120166A3 (en) Antibodies for selective apoptosis of cells
EA200500834A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
WO2010056889A3 (en) Use of an antibody and a rare-earth based crystal
WO2022204713A3 (en) Antibodies to sars-cov-2
NO20070195L (no) Vaksine mot HPV16 og HPV18 og minst en annen HPV-type valgt fra HPV31, 45 eller 52
EA201171239A1 (ru) Способ детекции типа паппиломавируса человека (hpv)
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung